midazolam injection, 10 mg
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) (midazolam injection, 10 mg) is mechanism of action the exact mechanism of action for midazolam in the treatment of status epilepticus is not fully understood, but is thought to involve potentiation of gabaergic neurotransmission resulting from binding at the benzodiazepine site of the gabaa receptor. Approved for status epilepticus in adults. First approved in 2022.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
Midazolam hydrochloride autoinjector is a benzodiazepine formulated for intramuscular injection delivering 10 mg per dose. It treats status epilepticus in adults by potentiating GABAergic neurotransmission at the GABAA receptor. The autoinjector delivery mechanism enables rapid, pre-hospital administration with median time to peak plasma concentration of approximately 30 minutes.
Product is in peak commercial phase with moderate competitive pressure (30%), positioning the brand team for active market penetration and managed care contracting.
Mechanism of Action The exact mechanism of action for midazolam in the treatment of status epilepticus is not fully understood, but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. Pharmacodynamics The effects…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Benzodiazepine
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on the midazolam autoinjector offers exposure to specialty neurology/emergency medicine markets with focus on rapid commercialization of a differentiated delivery device. Career progression emphasizes market access, healthcare provider education, and formulary placement rather than clinical development.